Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Multiple sclerosis: an immune or neurodegenerative disorder?
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Immunomodulatory effects of Vitamin D in multiple sclerosis.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Dynamic regulatory network controlling TH17 cell differentiation.
BTG Commences Phase IIa Study of Multiple Sclerosis
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
4-aminopyridine toxicity: a case report and review of the literature.
Application of fullerenes in nanomedicine: an update.
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Vitamin D intake and incidence of multiple sclerosis.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?

Pages